Greenlight Biosciences Holdings (NASDAQ: GRNA) Collaborates With Serum Institute of India, Pvt, Ltd

Greenlight Biosciences Holdings (NASDAQ: GRNA) and Serum Institute of India (SII), Pvt, Ltd., have a licensing agreement to increase access to messenger RNA-based products globally.

The parties believe in promoting vaccine equity

SII produces and sells the highest doses of vaccines in the world. Greenlight Biosciences, on the other hand, has an RNA platform that focuses on commercialization, manufacturing, development, design, and discovery of products to improve plant, animal, and human health.

Furthermore, the agreement between the two parties shows their dedication to improving vaccine equity. The companies plan to develop many RNA messenger products annually to help billions of patients.

The companies will market the vaccines in different locations

Greenlight Biosciences will give SII access to its technology to commercialize, manufacture and develop a maximum of three messenger RNAs in places with a population of over 5 billion. These markets include Asia (apart from South Korea, Japan, and China), the Middle East, Latin America, and Africa.

According to SII’s CEO, Adar Poonawalla, its plan to ensure healthcare is equitable aligns with Greenlight’s. Messenger RNA vaccines will also reduce the suffering from diseases that can be prevented through immunization.

SII could expand its agreement to include two more Messenger RNA therapies and vaccines in the future. Furthermore, Greenlight could commercialize and develop the same Messenger RNA products in different locations. These include South Korea, Japan, China, New Zealand, Australia, Europe, and North America.

Greenlight will find and develop potential Messenger RNA vaccines. The company will begin with a vaccine for shingles. After this, SII will progress to commercializing, manufacturing, and clinical development.

In line with their agreement, Greenlight will move its current clinical production process to Pune, India, where SII is located. SII will conduct clinical trials for the products. If the therapies and vaccines are successful, SII will produce them in sufficient amounts.

According to Greenlight’s CEO, Andrey Zarur, the company is glad to partner with SII as it is the most prominent producer of vaccines. The two companies are also dedicated to ensuring Messenger RNA vaccines are available to all populations. For this reason, the agreement proves Greenlight’s dedication to making healthcare accessible to people of all backgrounds.

SII has also invested $10 million in Greenlight Biosciences.